Abraxis BioScience, Inc. Reports Record First Quarter 2006 Adjusted Earnings Per Share, Excluding Primarily Stock Option Expense, Of $0.41, An Increase Of 21 Percent

LOS ANGELES--(BUSINESS WIRE)--April 28, 2006--Abraxis BioScience, Inc. (Nasdaq:ABBI - News), an integrated, global biopharmaceutical company, today reported the financial results of its predecessor company, American Pharmaceutical Partners (APP), for the first quarter ended March 31, 2006. On April 18, 2006 subsequent to the end of the first quarter, APP completed the merger with its parent company, American BioScience, to form Abraxis BioScience. Accordingly, the financial results presented in this news release are for APP on a stand-alone basis.